Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects

Psychiatry Res. 1982 Aug;7(1):1-7. doi: 10.1016/0165-1781(82)90047-6.

Abstract

Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use
  • Chronic Disease
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Growth Hormone / blood*
  • Humans
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Naloxone / therapeutic use*
  • Prolactin / blood*
  • Psychiatric Status Rating Scales
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*

Substances

  • Antipsychotic Agents
  • Naloxone
  • Prolactin
  • Growth Hormone